Agenda
May 29th, 2008
8:30-9:00 Registration and Morning Coffee
9:00 Chair’s Opening Remarks
Dr Brian Lovatt, Chief Executive Officer, Vision Healthcare Research, UK
9:10 Pricing of Pharmaceuticals in Europe
Presentation to cover:
- Value-based pricing;
- Price-volume agreements;
- Therapeutic reference pricing;
- Risk-sharing agreements;
- The off-patent market: generic competition; and
- Key trends for the future
Dr Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics, Whitehall, London, UK
9:50 NICE and Risk Sharing/Capping Schemes
Presentation to cover:
- NICE guidance development process and opportunities to engage with industry;
- Policy developments: OFT report on pricing and risk sharing schemes;
- Recommendations of Health Select Committee enquiry into NICE;
- Case study: Velcade for multiple myeloma: a risk sharing scheme;
- The role of NICE in incentivising good value innovation
Dr Kalipso Chalkidou, Associate Director of Research and Development, National Institute for Health and Clinical Effectiveness, London, UK
10:30-11:00 Networking and Refreshment Break
11:00 European Union Market Access: Strategies for Success
Presentation to cover:
- Defining Value
- Medical & Marketing working together with the same goals
- How do you cover 27 markets in your pricing strategy
- An Aide Memoir for EU Market Access
Dr Brian Lovatt, Chief Executive Officer, Vision Healthcare Research, UK
11:40 Comparative Assessment of Generic Medicines
Presentation to cover:
- Trends affecting pricing of generic medicines in Europe;
- Impact of Indian manufacturers on European generics;
- Pricing variations between European countries;
- Competition by discounting;
- Market incentives within national reference-pricing systems;
- Strategies to deliver competitive pricing
Professor Steven Simoens, Research Centre for Pharmaceutical Care and Pharmacoeconomics, Katholieke Universiteit Leuven, Belgium
12:20-1:50 Lunch
2:00 Health Economics in the Era of Biologics
Presentation to cover:
- Market trends and changing health policy landscape;
- Health economics considerations related to biotechnology medicines;
- Data mining, cost-effectiveness, and financing issues;
- Value-based payer and market access strategies;
- Outlook for biologics
Mr Ulf Staginnus, Associate Director Outcomes Research Iberia and EMEA, Spain
2:40 Managing the Complexity of Pricing and Reimbursement in a Globalizing World
Presentation to cover:
- Social systems and specific pricing and reimbursement approaches;
- Challenges for drug developers and marketing in ever-changing social systems;
- Complexity of ‘fourth hurdle’ issues and how to manage these
Dr Dieter Russmann, Vice President Global Customer Strategy, Service Leader, Pricing & Reimbursement Europe, PAREXEL Consulting, Germany
3:20-3:40 Networking and Refreshment Break
3:40 IQWiG’s Methods for Assessment of the Relation of Benefits to Cost - A Case of Health Economists in Straitjackets?
Presentation to include:
- Evaluation of IQWiG’s plans for economic evaluations of pharmaceuticals;
- Initial reactions to a still-evolving plan;
- Role of the Expert Panel;
- Issues for clarification;
- Implications for limitations of the plan.
Brian Rittenhouse, Ph.D., Senior Director and Head, Strategic Pricing & Reimbursement, Schering Plough Corporation, USA
4:20 European Pricing Models and Preparing for Market Access
Presentation will discuss the following:
- Reference pricing at international and national level
- Analytical construct for P&R strategies
- Formulary management
Ernst J. Johannes, MD, Executive Director, Global Practice Lead Reimbursement, Quintiles Global Consulting, The Netherlands
5:00 Chairman’s closing remarks
Dr Brian Lovatt, Chief Executive Officer, Vision Healthcare Research, UK
5:20 Drinks and networking